UK Markets closed

Organon & Co. (OGN)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
38.90+0.34 (+0.88%)
At close: 04:04PM EDT
38.48 -0.42 (-1.08%)
After hours: 05:57PM EDT
Sign in to post a message.
  • H
    Howie
    Even at 36 the stock is cheap. 253.5 million shares and an Enterprise Value of 17.7 billion. 6.3 billion in revenue. Net profit margin above 20%. EBITDA of 2 billion. Growth is ahead. Should trade for 10 times EBITDA. Add another 2.5 billion with 253 million shares and we should have another 10 dollars in upside in 2022.
  • H
    Howie
    Good Conference Call. Lots of growth and putting LOE risk worries behind them. Things looking up with mid 2023 launch of Humira biosimilar. 100 billion in drugs going off patent in the next decade. Biosimilars grew 22% in Q1. 49 established brand portfolio holding its own with roughly 1.1 billion in revenue per quarter. Business Development outlook looks strong. Stock looks promising over the next 24 months.
  • T
    Turpona
    Q1 2022: Net income from continuing operations of $348 million, or $1.36 per diluted share; Adjusted net income from continuing operations of $420 million, or $1.65 per diluted share
  • G
    Gary
    I would expect this stock to hold its SP until ex div.
  • D
    Dave
    Not even great earnings will keep a stock up in this market.

    Organon (NYSE:OGN) reported quarterly earnings of $1.65 per share which beat the analyst consensus estimate of $1.30 by 26.92 percent. The company reported quarterly sales of $1.57 billion which beat the analyst consensus estimate of $1.52 billion by 3.09 percent.
  • G
    Gary
    I’m out! Had a nice run I’ll reload later!
  • H
    Howie
    33.39 Too much. It is obvious the game here. They crave action. Just action junkies.
  • H
    Howie
    Gary - which trading desk do you work for? How many shares are you looking to buy today?
  • C
    Ctahoot
    PE of 6….I’m not selling
  • H
    Howie
    The Goldman Sachs Group initiated coverage on shares of Organon & Co.  in a report released on Wednesday. The brokerage set a “buy” rating and a $40.00 price target on the stock. 
  • H
    Howie
    Looking attractive once again. I give this market maker credit. He obviously knows how to make money scalping shares. Average volume is 2.2 million. Daily pay of 22 thousand is an honest days work. How many would argue with a 100K a week or over 5 million a year buying on the bid and selling on the ask.
  • G
    Gary
    I’ll cover today…. Should be a nice red day!
  • D
    Dave
    I know why it is down over 3% today:
    Organon Q1 EPS $1.65 Beats $1.30 Estimate, Sales $1.57B Beat $1.52B Estimate
  • Y
    Yahoo Finance Insights
    Organon & is up 5.09% to 34.88
  • C
    C. Craig
    Who sold a MILLION shares at the close today 4/18/22, and for what reason? This stock isn't the cash cow it was supposed to be. Did one of the drugs fail approval or what?
  • S
    Sigrid V
    Why would Organon fall the day -- March 31st -- it announced a partnership with DARE?
  • H
    Howie
    Get ready cause it is coming....

    (Reuters) - AbbVie Inc missed Wall Street estimates for first-quarter sales on Friday, hurt by European competition for its blockbuster rheumatoid arthritis drug Humira.
  • H
    Howie
    From Scrip online...

    Organon commercial director and lead for the South Asia Region, Anjan Sen, lays out how the Merck spin-out expects to scale up activities in markets like India. A mix of new products, targeted repurposing efforts and access-driven pricing are part of the strategy that could potentially see the company double its presence in the region.

    https://scrip.pharmaintelligence.informa.com/SC146193/How-Organon-Expects-To-Steer-Its-Womens-Health-Engine-In-India
  • H
    Howie
    Happy to take any shares under 32. The clowns trying to paint the tape should be investigated.
  • G
    Gary
    Hope you guys sold and started to short this… what applies to Vitralis will happen to organon. Short or sell this now!

    From Piper Sandler

    QUOTE
    ... cash flow sustainability is "now even more problematic," Amsellem tells investors in a research note ...
    UNQUOTE

    I have been flagging this concern for a while now; I would have felt more comfortable in the sustainability of FCF if inflation is at a 2-3% historical normal, but with a 9-10% inflation, FCF margins can evaporate very quickly if there is no pricing power

    And the YoY revenue decline of 1% during Q1 shows the pricing weakness (that 1% = volume growth x ASP increase, btw), so it is safe to say that ASPs have been stagnant at best over the past year

    They can't cut costs fast enough to offset that level of inflation; the only solution is to increase prices but cut throat competition (including from Indian manufacturers) and exposure to government procurement arrangements make it difficult to increase pricing